LENZ Therapeutics LENZ
Report of Independent Registered Public Accounting Firm
- Form
- 8-K
- Filed
- Importance
- Routine
- Accession
- 0001628280-24-012633
- Completes an acquisition or sale of assets (2.01)
- Sells unregistered shares (3.02)
- Changes shareholder rights (3.03)
- Changes its auditor (4.01)
- Reports a change in control (5.01)
- Reports an executive or board change (5.02)
- Amends its charter or bylaws (5.03)
- Changes its ethics code (5.05)
- Changes its shell company status (5.06)
- Makes a Regulation FD disclosure (7.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- ImmunityBio IBRX public float $690M, Jun 30, 2025
- Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
- Immunome IMNM public float $729M, Jun 30, 2025
- Anaptysbio ANAB public float $633M, Dec 31, 2025
- Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
